Preclinical Models for Evaluating Bispecific Antibodies Targeting PD-1 and VEGF

Although PD-1 checkpoint inhibitors have transformed cancer treatment, therapeutic resistance remains a significant challenge. Bispecific antibodies co-targeting PD-1 and VEGF offer the potential to simultaneously restore T-cell immunity and inhibit tumor angiogenesis. GemPharmatech developed an integrated preclinical platform using complementary humanized mouse models to evaluate such dual-targeting agents. In a BALB/c-hPD-1/hPD-L1 dual-humanized model bearing CT26-hPD-L1-hVEGFA tumors, the PD-1/VEGF bispecific antibody Ivonescimab demonstrated superior tumor growth inhibition compared to single-pathway blockade. Complementary studies in PBMC-humanized NCG mice further confirmed robust T-cell-mediated antitumor activity across multiple tumor types. This platform enables comprehensive translational evaluation of next-generation PD-1/VEGF bispecific antibodies.